Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Af irms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EB ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-Q __________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to Commission File Number 001-37795 _______________________ ...

Revenue Performance - For the three months ended March 31, 2025, net revenue was 100% compared to 100% in the same period of 2024, with total revenue slightly decreasing from 101.5% to 101.4%[129] - Consolidated total revenue increased by $18.3 million, or 6.8%, to $287.4 million for the three months ended March 31, 2025, compared to $269.1 million for the same period in 2024[132] - Consolidated net revenue increased by $18.4 million, or 6.9%, to $283.6 million for the three months ended March 31, 2025, with Executive Search net revenue rising by $11.9 million, or 5.9%[133] - The Americas segment reported net revenue of $144.4 million, an increase of 5.7%, with a 3.6% rise in the number of executive search confirmations[146] - The Europe segment reported net revenue of $45.4 million, an increase of 9.4%, driven by a 7.5% increase in executive search confirmations[150] - The Asia Pacific segment reported net revenue of $23.6 million for the three months ended March 31, 2025, an increase of 1.2% compared to the prior year[154] - The On-Demand Talent segment reported net revenue of $42.6 million for the three months ended March 31, 2025, an increase of 12.4% compared to the prior year[158] - The Heidrick Consulting segment reported net revenue of $27.6 million for the three months ended March 31, 2025, an increase of 6.8% compared to the prior year[163] Operating Expenses and Profitability - Operating expenses increased to 95.6% of net revenue in Q1 2025 from 95.3% in Q1 2024, with salaries and benefits rising to 66.8% from 65.8%[129] - Net income for Q1 2025 was 4.7%, down from 5.3% in Q1 2024, indicating a decline in profitability[129] - Consolidated salaries and benefits expense increased by $15.1 million, or 8.6%, to $189.5 million for the three months ended March 31, 2025[135] - Consolidated general and administrative expenses increased by $0.1 million, or 0.1%, to $41.4 million for the three months ended March 31, 2025[137] - Consolidated cost of services increased by $2.6 million, or 9.6%, to $30.1 million for the three months ended March 31, 2025[139] - Research and development expenses increased by $0.7 million, or 11.8%, to $6.4 million for the three months ended March 31, 2025[141] - The compensation model for consultants ties a portion of their pay to net revenue generated, impacting overall compensation expense and operating margin[127] Key Performance Indicators - Adjusted EBITDA and Adjusted EBITDA margin are key performance indicators, with the potential for improvement as revenue increases without a proportional rise in operating costs[122] - Adjusted EBITDA was $29.1 million for the three months ended March 31, 2025, an increase of $3.3 million, or 12.6%, compared to $25.9 million for the same period in 2024[142] - Adjusted EBITDA margin improved to 10.3% for the three months ended March 31, 2025, compared to 9.8% for the same period in 2024[142] - Adjusted EBITDA for the On-Demand Talent segment improved to $0.4 million for the three months ended March 31, 2025, compared to an Adjusted EBITDA loss of $0.9 million in the prior year[162] - The Global Operations Support segment reported an Adjusted EBITDA loss of $16.9 million for the three months ended March 31, 2025, a decrease of $2.2 million compared to the prior year[170] Strategic Focus and Initiatives - The company is focused on expanding revenue streams beyond executive search through the One Heidrick strategy and the upcoming Heidrick Digital[120] - Heidrick Consulting has pivoted to create new digital solutions for leadership assessments and team acceleration, which can be delivered virtually[119] - The company emphasizes a data-driven approach in executive search, utilizing the Heidrick Leadership Framework and Heidrick Connect for enhanced client engagement[113] - The company employs over 500 consultants globally, leveraging their expertise to enhance leadership effectiveness for clients[110] Risks and Financial Position - The company faces various risks, including macroeconomic conditions, cybersecurity threats, and geopolitical instability, which could materially affect future performance[109] - Cash used in operating activities was $232.2 million for the three months ended March 31, 2025, primarily due to a decrease in accrued expenses of $199.3 million[177] - Cash, cash equivalents, and marketable securities totaled $324.7 million as of March 31, 2025, including $170.6 million held by foreign subsidiaries[176] - The company had no outstanding borrowings as of March 31, 2025, and was in compliance with financial covenants under the Amended Credit Agreement[175] - The company entered into a committed revolving credit facility of $100 million on March 17, 2025, with a maturity date extended to March 17, 2030[173] Currency and Foreign Operations - A 10% change in average exchange rates for foreign currencies could impact net income by approximately $0.6 million for the three months ended March 31, 2025[188] - The company operates in multiple regions including the Americas, Europe, and Asia Pacific, using various currencies[188] - Revenue earned in each country is generally matched with associated expenses, reducing currency risk to earnings[188] - Certain assets and liabilities are denominated in currencies other than the U.S. dollar, leading to potential valuation fluctuations[188] - Local currencies of subsidiaries are generally designated as functional currencies, affecting translation into U.S. dollars[188] - Financial information by segment is detailed in Note 15 of the Quarterly Report on Form 10-Q[188]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2520134 (State or other jurisdiction ...

Exhibit 99.1 Investor Relations inquiries: News Media inquiries: Justin Schoenberg Keoni Wagner Matson, Inc. Matson, Inc. 510.628.4234 510.628.4534 jschoenberg@matson.com kwagner@matson.com FOR IMMEDIATE RELEASE MATSON, INC. ANNOUNCES FIRST QUARTER 2025 RESULTS HONOLULU, Hawaii (May 5, 2025) – Matson, Inc. ("Matson" or the "Company") (NYSE: MATX), a leading U.S. carrier in the Pacific, today reported net income of $72.3 million, or $2.18 per diluted share, for the quarter ended March 31, 2025. Net income fo ...

Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Exhibit 99.1 ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates A ...

Exhibit 99.1 Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments ...

Vertex Reports First Quarter 2025 Financial Results — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Four programs already in pivotal development, with pivotal study of pove in primary membranous nephropathy (pMN) to start this year — BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, a ...

DENNY'S CORPORATION REPORTS RESULTS FOR FIRST QUARTER 2025 SPARTANBURG, S.C., May 5, 2025 - Denny's Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today reported results for its first quarter ended March 26, 2025 and provided a business update on the Company's operations. Franchise and license revenue was $57.7 million compared to $57.6 million for the prior year quarter. This increase was primarily driven by higher local advertising co- ...